These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 24249647

  • 21. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
    Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J.
    Pediatr Nephrol; 2012 Dec; 27(12):2323-6. PubMed ID: 22890512
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S.
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [Abstract] [Full Text] [Related]

  • 23. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.
    Dorresteijn EM, van de Kar NC, Cransberg K.
    Pediatr Nephrol; 2012 Jul; 27(7):1193-5. PubMed ID: 22399074
    [Abstract] [Full Text] [Related]

  • 24. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [Abstract] [Full Text] [Related]

  • 25. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.
    Am J Nephrol; 2018 Jun; 48(3):225-233. PubMed ID: 30205388
    [Abstract] [Full Text] [Related]

  • 26. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Jun; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 27. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [Abstract] [Full Text] [Related]

  • 30. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 31. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
    Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G.
    Am J Case Rep; 2019 Oct 04; 20():1460-1465. PubMed ID: 31582717
    [Abstract] [Full Text] [Related]

  • 32. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S, Bhalla A, Alasfar S, Alachkar N.
    BMC Nephrol; 2020 May 20; 21(1):189. PubMed ID: 32434487
    [Abstract] [Full Text] [Related]

  • 33. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
    Carter S, Hewitt I, Kausman J.
    Nephrology (Carlton); 2017 Feb 20; 22 Suppl 1():7-10. PubMed ID: 28176479
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R, San A, Kurtkoti J, Parnham A.
    Nephrology (Carlton); 2017 Feb 20; 22 Suppl 1():32-35. PubMed ID: 28176475
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
    Chua J, Paizis K, He SZ, Mount P.
    Nephrology (Carlton); 2017 Feb 20; 22 Suppl 1():18-22. PubMed ID: 28176472
    [Abstract] [Full Text] [Related]

  • 38. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
    Kerboua KE, Haiba F, Batouche D.
    J Immunoassay Immunochem; 2017 Feb 20; 38(2):178-189. PubMed ID: 27617501
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Feb 20; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.